AI / LLMChina
← Sticker Wall
JOURNEY · DETAIL
Airdoc: The Compliant Global Expansion Path of China's First AI Medical Imaging Stock
Founded: Zhang Dalei · Beijing Airdoc Technology Co., Ltd.
JOURNEY
Key Fields
FIELD STAMPSIndustryAI / LLM
RegionChina
ScaleMid-size
ChannelOther
Origin
Founder Zhang Dalei previously worked in internet programming and resolved to enter the medical AI track after family members experienced a misdiagnosis. Around 2015, he chose to start from retinal imaging rather than pursuing full-department AI diagnosis. Retinal images can reflect systemic disease signals across multiple body systems, have a high degree of data standardization, and feature clear single-disease scenarios, making them one of the most ideal entry points for AI-assisted diagnosis. The initial team consisted of fewer than 10 people with limited starting capital, relying on self-funding by the founder and early angel investment to support R&D.
Milestones
2015
Startup Stage Turning Point
In 2015, Zhang Dalei left internet programming to found Airdoc with a team of fewer than 10 people, choosing retinal image analysis as their first key breakthrough direction. At that time, domestic AI healthcare had not yet formed an established track, investors had extremely low awareness of medical AI, and the first round of financing was extremely difficult. The team temporarily relied on the founder's savings to sustain R&D.
2017
Product Validation Failure
The team attempted to rapidly expand the number of partner hospitals through a free trial strategy, but actual product accuracy in real clinical scenarios fell far short of laboratory data, and multiple hospitals did not renew after the trial. At the same time, there was no clear approval pathway for AI-assisted diagnosis in China, making it impossible to charge for products compliantly, resulting in a massive waste of time and capital. This period lasted from 2017 to 2018.
2020
Compliance Breakthrough PMF
In 2020, Airdoc obtained China's first NMPA Class III medical device registration certificate for retinal image-based AI-assisted diagnosis, marking the official qualification of the product for compliant commercial charging. This milestone was a critical turning point for the entire AI medical imaging industry, signifying that hospitals could integrate AI-assisted diagnosis into formal diagnosis and treatment workflows and charge for it.
2021
IPO Growth
Airdoc was listed on the Main Board of the Hong Kong Stock Exchange, becoming the first AI medical imaging stock in China. The proceeds from the IPO were mainly used for product line expansion and international layout. However, it faced pressure of breaking the issue price on its first day of trading. The market remained skeptical about the profitability of AI healthcare enterprises, and the stock price continued to face pressure, reflecting the capital market's cautious attitude toward the commercial prospects of this track.
2022
Global Expansion Exploration Failure
Initiated the internationalization strategy, targeting the US market as the first stop. However, the FDA approval cycle was lengthy and compliance adaptation costs were high. The team hit major hurdles in regulatory adaptation, and clinical trial expenses far exceeded the budget. They were later forced to adjust strategy and pivot to emerging markets such as Southeast Asia and the Middle East, but overseas revenue still accounted for less than 10%, and international progress fell significantly short of expectations. This period lasted from 2022 to 2023.
2024
Scaling & Overseas Breakthrough Turning Point
The company pushed toward the 100 million yuan revenue target, expanding its product line from single-disease retinal conditions to all-department imaging AI, while also entering grassroots community screening and other sinking scenarios. Regarding overseas expansion, it gradually obtained CE certification and landed benchmark projects in the Southeast Asian market. However, during the transition of the business model from project-based to SaaS subscription, hospital payment willingness and retention rates remained core challenges. This period lasted from 2024 to 2026.
Turning Points
- Obtained China's first NMPA Class III medical device registration certificate for AI retinal imaging, becoming a pioneer in industry compliance pathways.
- Went public on the HKEX in 2021 as the first AI medical imaging stock, but breaking the issue price on day one exposed capital market skepticism regarding the track's profitability.
- After setbacks in the US as the first overseas stop, was forced to pivot to Southeast Asia and the Middle East, shifting the internationalization path from high-profile to pragmatic and gradual.
Failures & Pitfalls
- The initial free trial strategy led to many hospitals not converting to paid usage after trials, resulting in extremely low commercialization efficiency.
- FDA approval timelines and costs far exceeded expectations, forcing the US expansion plan to be shelved in favor of emerging markets.
- Post-IPO stock price remained under persistent pressure, reflecting that the overall profitability dilemma of the AI medical imaging track had not yet been resolved.
关键成功要素
- Chose retinal imaging—a niche segment with high standardization and the ability to reflect systemic diseases—as the entry point, avoiding full-department AI diagnosis in the early stages.
- Securing the NMPA Class III certificate first built strong compliance barriers, leaving latecomers to follow rather than surpass the approval pathway.
- Shifted the overseas expansion path from the US to emerging markets in Southeast Asia and the Middle East, which better aligns with the penetration logic of AI imaging products in regions with insufficient medical infrastructure.
- Expanded from single-disease retinal imaging to all-department imaging and grassroots screening, requiring a balance between technical depth and scenario breadth.
Lessons
- The core barrier of AI medical imaging lies not in algorithms, but in compliance qualifications and accumulated clinical validation data. The enterprise that secures the certificate first enjoys channel dividend advantages.
- A free trial strategy is unfeasible in serious medical scenarios; hospital-end payments require support from compliance qualifications rather than being driven purely by product experience.
- Target market selection for global expansion must match product maturity and regulatory entry difficulty. Emerging markets are more suitable than the US for early commercialization of AI imaging.
- Transitioning from project-based sales to SaaS subscription is key for AI medical imaging enterprises to elevate valuations and profitability, but the shift in hospital payment habits is extremely slow.
Core Data
- 营收规模：Targeted approx. 100 million RMB in annual revenue in 2024 (based on public disclosures, independent verification pending)
- 上市状态：Listed on the HKEX Main Board in November 2021 (based on public disclosures, independent verification pending)
- 合规资质：China's first NMPA Class III medical device registration certificate for AI retinal imaging (based on public disclosures, independent verification pending)
- 医院覆盖：Hundreds of hospitals and grassroots medical institutions nationwide (based on public disclosures, independent verification pending)
- 海外营收占比：Overseas revenue accounted for less than 10% during global expansion (based on public disclosures, independent verification pending)
- 团队规模：Ranged approximately between 200 and 300 employees (based on public disclosures, independent verification pending)
Competitors / Peers
Airdoc faces multiple competitors in the AI medical imaging track: domestically, Deyi Technology is challenging the capital markets positioned as the first medical imaging large model stock; SenseTime Medical leverages 500 million in financing and large model technology to enter all-department imaging diagnosis; Shukun Technology continues its sprint on the Hong Kong Stock Exchange despite three years of 800 million in losses; Yitu Healthcare retains technical accumulation after internal restructuring. Internationally, Infervision positions itself globally with leading AI medical imaging technology for overseas markets, while Changxiang aggressively attacks export markets after capturing seventy percent of medical centers in Taiwan's pathology AI sector. The overall competitive landscape exhibits a trend toward diversified technical routes and business models evolving from single-disease applications to large-model foundation bases.